PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Cecilia Carmen Carpio Segura,
Manjusha Namuduri,
Dishan Liu,
Nickolas A. Sophos,
Min Zhu,
Ayesha Sabir,
Jurriaan Brouwer-Visser,
Aafia Chaudhry,
Hesham Mohamed,
Alejandro Martin Garcia-Sancho
Affiliations
Cecilia Carmen Carpio Segura
1 Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Department of Hematology, Experimental Hematology, Barcelona, Spain
Manjusha Namuduri
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Dishan Liu
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Nickolas A. Sophos
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Min Zhu
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Ayesha Sabir
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Jurriaan Brouwer-Visser
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Aafia Chaudhry
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Hesham Mohamed
2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Alejandro Martin Garcia-Sancho
3 Hospital Universitario de Salamanca, IBSAL, Department of Hematology, Salamanca, Spain
